Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026)

Alvotech (ALVO) posted Net Income towards Common Stockholders of $1.0 million for Q1 2026, down 99.06% on a QoQ basis from $109.7 million in Q4 2025, and down 99.06% year-over-year from $109.7 million in Q1 2025.

Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Alvotech's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 99.06% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$165.1 million (up 38.58% YoY) and the FY2025 annual result came in at $109.7 million, up 144.43% from the prior year.
  • Net Income towards Common Stockholders was $1.0 million for Q1 2026 at Alvotech, down from $109.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $264.7 million in Q2 2022 and bottomed at -$651.1 million in Q4 2023.
  • A 5-year average of -$91.4 million and a median of -$246152.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 362.17% — and 2025, when it jumped 51566.14%.
  • Alvotech's Net Income towards Common Stockholders stood at -$540.7 million in 2022, then retreated by 20.43% to -$651.1 million in 2023, then jumped by 65.69% to -$223.4 million in 2024, then soared by 149.1% to $109.7 million in 2025, then slumped by 99.06% to $1.0 million in 2026.
  • Business Quant data shows ALVO's Net Income towards Common Stockholders at $1.0 million in Q1 2026, $109.7 million in Q4 2025, and -$307.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Alvotech 907.91 Mn 907.91 Mn 5.09 Mn 1.03 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.03 Mn
Dec 31, 2025 109.68 Mn
Sep 30, 2025 -307.87 Mn
Jun 30, 2025 32.04 Mn
Mar 31, 2025 109.68 Mn
Dec 31, 2024 -223.39 Mn
Sep 30, 2024 -303.58 Mn
Jun 30, 2024 148.46 Mn
Mar 31, 2024 -213,111.00
Dec 31, 2023 -651.14 Mn
Aug 31, 2023 -86.85 Mn
Jun 30, 2023 138.48 Mn
Mar 31, 2023 -246,152.00
Dec 31, 2022 -540.69 Mn
Aug 31, 2022 -184.47 Mn
Jun 30, 2022 264.69 Mn
Mar 31, 2022 -58.90 Mn
Dec 31, 2021 206.23 Mn
Sep 30, 2021 -33.79 Mn